← USPTO Patent Grants

Methods and compositions for improving exercise performance, single ventricular performance, cardiac output and myocardial performance index (MPI) in single ventricular heart disease, using udenafil compositions

Grant US12576081B2 Kind: B2 Mar 17, 2026

Assignee

Mezzion Pharma Co., Ltd.

Inventors

James L. Yeager, David J. Goldberg, Stephen M. Paridon

Abstract

Various methods and compositions for treating single ventricle heart disease (SVHD) patients, including patients who have undergone Fontan surgery and who have Fontan circulation (Fontan patient), to improve exercise performance, single ventricular performance, cardiac output and myocardial performance index (MPI) in the SVHD patients, including the Fontan patients, using udenafil compositions. In one exemplary embodiment, the methods of the present invention include administering an effective amount of udenafil or a pharmaceutically acceptable salt thereof to a SVHD patient, including a Fontan, to improve the ventricular performance of the SVHD patient's, including the Fontan patient's, single functioning ventricle. In another exemplary embodiment, the methods of the present invention include administering an effective amount of udenafil or a pharmaceutically acceptable salt thereof to a SVHD patient, including a Fontan patient, to improve the SVHD patient's, including the Fontan patient's, MPI. In still another exemplary embodiment, the methods of the present invention include administering an effective amount of udenafil or a pharmaceutically acceptable salt thereof to a SVHD patient, including a Fontan patient, to improve the SVHD patient's, including the Fontan patient's, cardiac output. In yet another exemplary embodiment, the methods of the present invention include administering an effective amount of udenafil or a pharmaceutically acceptable salt thereof to a SVHD patient, including a Fontan patient, who is about 6 years of age or older, to improve at least one or more or all of the following in the SVHD patient, including the Fontan patient: (a) ventricular performance of the SVHD patient's, including a Fontan patient's, single functioning ventricle as measured by MPI; (b) exercise capacity as measured by oxygen consumption at anaerobic threshold (VAT); (c) exercise capacity as measured by oxygen consumption at maximal effort or max VO2; (d) work rate at VAT; (e) VE/VCO2 at VAT; diastolic blood pressure at rest; and (g) oxygen saturation (%) at rest.

CPC Classifications

A61K 31/519 A61K 9/2013 A61P 43/00

Filing Date

2020-07-24

Application No.

16938642

Claims

13